Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

$24.99

Return on Equity (ROE)
since 2005

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Gilead Sciences Inc., ROE, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions


The financial data reveals notable fluctuations in net income attributable to the company and corresponding changes in stockholders’ equity over the period analyzed. Net income exhibited considerable volatility, with years of both significant gains and losses. For instance, a marked loss occurred early in the series, followed by a recovery with steady growth leading up to a peak in 2014 and 2015. Subsequently, net income levels displayed a declining trend with occasional rebounds, but overall stabilizing at moderate levels in the most recent years.

Stockholders’ equity demonstrated a generally positive trajectory, increasing substantially from the beginning of the period through to the mid-2010s. After reaching a peak around 2019, equity levels showed some fluctuations but remained relatively stable with mild decreases towards the final years noted. This suggests ongoing accumulation of retained earnings or other equity increases over time, with some recent pressures or distributions tempering growth.

Return on Equity (ROE) percentages mirror the volatility seen in net income. ROE was highly variable initially, including negative values indicating negative profitability in relation to equity. In the years following, ROE maintained relatively high levels for an extended period, reaching exceptional peaks exceeding 90% around the mid-2010s, reflecting strong profitability relative to equity. More recent years show a decline in ROE towards moderate single digits, pointing to reduced efficiency in generating returns from equity capital during these periods.

Net Income Trends
Net income experienced significant fluctuation with an early loss turning into a multi-year upward trend culminating in a peak around 2014-2015, followed by a general decline and stabilization at moderate positive values.
Stockholders’ Equity Trends
Stockholders’ equity generally increased over the timeframe, reflecting accumulation of earnings or capital injections, with some tapering and slight decline observed in the latter years.
Return on Equity (ROE)
ROE showed high variability, including early negative returns, a sustained period of strong profitability with peaks near 100%, and a recent decline indicating less efficient utilization of equity.
Overall Observations
The data indicates periods of strong financial performance interspersed with volatility. The company's ability to generate high returns on equity has diminished in recent years despite stable equity levels. Monitoring trends in profitability and equity efficiency will be critical for future financial assessments.

Comparison to Competitors

Gilead Sciences Inc., ROE, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Gilead Sciences Inc., ROE, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)